Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Tardive dyskinesia Stories

2013-01-25 12:25:43

NEW BRUNSWICK, N.J., Jan. 25, 2013 /PRNewswire-USNewswire/ -- Parkinson's disease affects one million people in the United States and seven million worldwide. While L-Dopa is effective in treating the disease symptoms, the vast majority of patients taking it chronically eventually develop L-Dopa Induced Dyskinesia (LID), abnormal involuntary movements that can be disabling. A new company, MentiNova, Inc., is exploring an oral medication that could reduce these uncontrollable, often chaotic...

2012-12-30 05:03:42

According to court documents, on December 10th, 2012, a Michigan man filed a products liability claim at Philadelphia Court of Common Pleas alleging he suffered tardive dyskinesia from his use of Reglan. In light of these news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Reglan side effects. [http://www.attorneyone.com/reglan-lawsuit/ San Diego, CA (PRWEB)...

2012-12-18 16:24:44

SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, dose titration trial of 90 subjects with moderate to severe tardive dyskinesia and underlying mood disorders, gastrointestinal disorders, and...

2012-11-27 16:26:02

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 2012 dbAccess BioFEST in Boston. The live presentation takes place on Tuesday, December 4 at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. If you are unable to attend...

2012-11-20 16:29:21

SAN DIEGO, Nov. 20, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 24(th) Annual Piper Jaffray Healthcare Conference in New York. The live presentation takes place on Tuesday, November 27 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com....

2012-11-06 12:27:34

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Lazard Capital Market's 9(th) Annual Healthcare Conference in New York. The live presentation takes place on Tuesday, November 13 at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at...

2012-10-31 15:25:31

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and nine months ended September 30, 2012. For the third quarter of 2012, the Company reported a net loss of $3.1 million, or $0.05 loss per share, compared to net income of $31.4 million, or income of $0.56 per fully diluted share outstanding, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $4.5...

2012-10-24 19:21:14

SAN DIEGO, Oct. 24, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2012 financial results after the Nasdaq market closes on Wednesday, October 31, 2012. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, October 31, 2012 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference...

2012-10-01 10:26:46

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, trial of 120 subjects with moderate to severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. Topline data is expected in...

2012-09-05 10:26:11

SAN DIEGO, Sept. 5, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York. The live presentation takes place on Wednesday, September 12 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com....